HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC
NCT06364007
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
HAIC+STRIDE+Len
Sponsor
Sulai Liu